Dear Colleagues,

It is our great pleasure to invite you to the 20th International Symposium on Pediatric Neuro-Oncology, ISPNO 2022, in Hamburg, Germany, from 12–15 June, 2022.

ISPNO is by far the largest international scientific meeting of multidisciplinary professionals in research, diagnosis, treatment, and rehabilitation of children and adolescents with tumors of the Central Nervous System. ISPNO 2022 will be co-hosted by the University Medical Center Hamburg-Eppendorf with its Department of Pediatric Hematology and Oncology, and the German Cancer Research Center (DKFZ) Heidelberg.

The program will include the most recent cutting-edge preclinical and clinical research from the fields of neurosurgery, neuroradiology, neuropathology, biology, radiotherapy, pediatric neuro-oncology, immunotherapy, late effects, rehabilitation, and nursing. We will also have state-of-the-art symposia, interdisciplinary sessions and round tables on the most challenging and timely topics in the field of pediatric neurooncology.

The vibrant and maritime metropolis of Hamburg, the second largest city of Germany, is located in Northern Germany. With its international airport only 20 minutes from the city center, it is easy to approach. The venue of ISPNO 2022, the Congress Center Hamburg (CCH Hamburg), is situated in the heart of the city.

We have planned ISPNO 2022 as a flexible hybrid meeting with live attendance in accordance with the rules for the pandemic. We are fully convinced, that these formats will ensure high participation numbers by multidisciplinary health-care professionals and scientists from all over the world.

For further information, please see our website.

www.ispno2022.de
## PRELIMINARY PROGRAM OVERVIEW

<table>
<thead>
<tr>
<th>Monday, 13th June 2022</th>
<th>Tuesday, 14th June 2022</th>
<th>Wednesday, 15th June 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room A</td>
<td>Room B</td>
<td>Room A</td>
</tr>
<tr>
<td>07:00–8:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal models</td>
<td>Nursing and palliative</td>
<td>Drug delivery</td>
</tr>
<tr>
<td>and preclinical testing</td>
<td>care</td>
<td>New statistical methods</td>
</tr>
<tr>
<td>08:00–8:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30–10:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low grade glioma (LGG)</td>
<td>Imaging</td>
<td>Craniopharyngioma &amp; other rare tumors</td>
</tr>
<tr>
<td>10:00–10:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30–12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medulloblasoma 1</td>
<td>Neurosurgery</td>
<td>Medulloblastoma 2</td>
</tr>
<tr>
<td>12:00–13:00</td>
<td></td>
<td>Tumor heterogeneity and resistance</td>
</tr>
<tr>
<td>Translating discoveries into therapies – How to conduct conclusive early phase clinical trials in pediatric neurooncology?</td>
<td>Award Session</td>
<td>Regulatory and ethical decisions &amp; parents involvement</td>
</tr>
<tr>
<td>13:00–13:30</td>
<td>Lunch break</td>
<td></td>
</tr>
<tr>
<td>13:30–14:30</td>
<td>Personalized medicine and phase III trials – how to reconcile the two seemingly contradictory concepts?</td>
<td>Neurodevelopment / human cell atlas</td>
</tr>
<tr>
<td>14:30–16:00</td>
<td>Ependymoma</td>
<td>High grade glioma (HGG) 2</td>
</tr>
<tr>
<td>16:00–16:30</td>
<td>Cancer Predisposition</td>
<td>Liquid biopsy / innovative diagnostics</td>
</tr>
<tr>
<td>16:30–17:30</td>
<td>Germ Cell Tumors (GCT)</td>
<td></td>
</tr>
<tr>
<td>17:45–19:00</td>
<td>Posterwalk</td>
<td></td>
</tr>
</tbody>
</table>

## VENUE

**Congress Center Hamburg (CCH)**  
Am Dammtor  
Marseiller Straße  
20355 Hamburg  
Germany

## SCIENTIFIC CHAIRS

**Prof. Dr. med. Stefan Rutkowski**  
Director of the Department for Pediatric Hematology and Oncology  
University Medical Center Hamburg-Eppendorf (UKE)  
Speaker of the Pediatric Brain Tumor Study Group of GPOH (HIT-Network)

**Prof. Dr. Stefan M. Pfister**  
Director Preclinical Program Hopp Children's Cancer Center Heidelberg (KITZ)  
Head, Division of Pediatric Neurooncology, DKFZ  
Deputy Head, KITZ Clinical Trial Unit (ZIPO) and Pediatric Brain Tumors, Heidelberg University Hospital

## PROJECT MANAGEMENT

**Regine Riechers**  
Department for Pediatric Hematology and Oncology  
University Hospital Hamburg-Eppendorf (UKE)

**Iris Oezen**  
Hopp Children's Cancer Center Heidelberg (KITZ)  
Heidelberg University Hospital

## CONGRESS ORGANIZER

**Universitätsklinikum Hamburg – Eppendorf, KdöR (UKE)**  
Martinistraße 52  
20246 Hamburg  
Email: pho@uke.de

**INTERPLAN**  
Congress, Meeting & Events Management AG  
Office Hamburg  
Sachsenstraße 6 | 20097 Hamburg  
Phone: +49 (0) 40 23 50 92 43  
Email: ispno@interplan.de

**www.ispno2022.de**
We are convinced that the entire Neuro-Oncology community is very much looking forward to meeting again in person at this landmark event in science and clinical practice after the compulsory break due to the pandemic. ISPNO 2022, as well as the preceding annual meeting of the SIOPE-Brain Tumor Group (June 11-12, 2022), will provide excellent opportunities for networking, and the social program is planned in accordance with the rules for the pandemic.

**CALL FOR ABSTRACTS**

**KEY DATES:**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABSTRACT SUBMISSION DEADLINE</strong></td>
<td>31 January 2022</td>
</tr>
<tr>
<td><strong>EARLY BIRD REGISTRATION</strong></td>
<td>01 February-19 April 2022</td>
</tr>
<tr>
<td><strong>ABSTRACT NOTIFICATIONS</strong></td>
<td>01 March-18 March 2022</td>
</tr>
<tr>
<td><strong>LATE REGISTRATION</strong></td>
<td>From 20 April 2022</td>
</tr>
</tbody>
</table>

Please find the link for submission on our website: [www.ispno.de/abstract-information](http://www.ispno.de/abstract-information)

**ABSTRACT GUIDELINES:**

- Maximum 300 words (without title)
- Plain text only, no graphics or diagrams
- Accepted submissions will be published on the ISPNO website and in an online supplement to the journal Neuro-Oncology
- Asian authors of the 10 best abstracts will receive a travel grant of up to 1000 EUR.

**ISPNO WELCOMES SUBMISSION OF ORIGINAL RESEARCH ON THE FOLLOWING TOPICS:**

- AT/RT
- Craniopharyngioma and Rare Tumors
- Diffuse Midline Glioma/DIPG
- Drug Delivery/Pharmacokinetics
- Early Phase Clinical Trials
- Ependymoma
- Epidemiology
- ETMR and other Embryonal Tumors
- Germ Cell Tumors
- High Grade Glioma
- Imaging
- Immunotherapy
- Low Grade Glioma
- Medulloblastoma
- Neurofibromatosis and other Predisposition syndromes
- Neuropsychology/Quality of Life
- Neurosurgery
- Nursing
- Others (not fitting any other category)
- Pathology/Classification
- Pediatric Neuro-Oncology in Low/Middle Income Countries
- Preclinical Models/Experimental Therapy/Drug Discovery
- Radiation Oncology
- Social Work/Patient Support/Palliative Care
- Tumor Biology (not fitting a specific disease category)
- Viral/Gene Therapy and other Novel Therapies

[www.ispno2022.de](http://www.ispno2022.de)